

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/23376 A1

(51) International Patent Classification⁷: **C07D 401/14**,
401/12, 401/06, 211/62, 405/14, 409/14, 417/12, A61K
31/454, A61P 7/02

(74) Agents: **JOHNSON, Philip et al.**; Johnson and Johnson,
One Johnson and Johnson Plaza, New Brunswick, NJ
08933 (US).

(21) International Application Number: PCT/US00/26163

(22) International Filing Date:
22 September 2000 (22.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/156,617 29 September 1999 (29.09.1999) US
09/667,134 21 September 2000 (21.09.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **ORTHO-MCNEIL PHARMACEUTICAL,
INC.** [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ
08869-0602 (US).


Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.*

(72) Inventors: **COSTANZO, Michael, J.**; 14 Breckenridge
Drive, Ivyland, PA 18974 (US). **HOEKSTRA, William,
J.**; 104 San Miguel Place, Chapel Hill, NC 27514 (US).
MARYANOFF, Bruce, E.; 4029 Devonshire Drive, Forest
Grove, PA 19477 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS**



(57) Abstract: The invention is directed to novel isonipecotamide derivatives of Formula (I), which are useful in treating integrin-mediated disorders.



WO 01/23376 A1

Title of the Invention

ISONIPECOTAMIDES FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS

5

Field of the Invention

This invention relates to certain novel compounds, their synthesis and methods for their use in treating integrin-mediated disorders. More particularly, this invention relates to isonipecotamide compounds that are $\alpha\nu\beta 3$, $\alpha\nu\beta 5$, GPIIb/IIIa, dual $\alpha\nu\beta 3$ /GPIIb/IIIa or dual $\alpha\nu\beta 3/\alpha\nu\beta 5$ integrin antagonists and methods for their use in treating a variety of integrin-mediated disorders.

10

Background of the Invention

15

Integrins are a widely expressed family of calcium- or magnesium-dependent $\alpha\beta$ heterodimeric cell surface receptors which bind to extracellular matrix adhesive proteins such as fibrinogen, fibronectin, vitronectin, and osteopontin. These transmembrane glycoproteins (GP's), known for their large extracellular domains, are classified by at least 8 known β subunits and 14 α subunits (S. A. Mousa, et al., *Emerging Therapeutic Targets*, 2000, 4, (2), 143-153). For example, the $\beta 1$ subfamily, also known as the very late antigen (VLA) subfamily, has the largest number of integrins (S. A. Mousa, et al., *Emerging Therapeutic Targets*, 2000, 4, (2), 144). The $\alpha\nu\beta 1$ subfamily further associates with various β subunits: $\beta 3$, $\beta 5$, $\beta 6$, $\beta 8$ and $\alpha IIb\beta 3$ (also referred to as GPIIb/IIIa) (S. A. Mousa, et al., *Emerging Therapeutic Targets*, 2000, 4, (2), 144, 147). Some of the disease states that have a strong $\beta 3$, $\beta 5$ and GPIIb/IIIa integrin component in their etiologies are unstable angina, thromboembolic disorders or atherosclerosis (GPIIb/IIIa); thrombosis or restenosis (GPIIb/IIIa or $\alpha\nu\beta 3$); restenosis (dual $\alpha\nu\beta 3$ /GPIIb/IIIa); rheumatoid arthritis, vascular disorders or osteoporosis ($\alpha\nu\beta 3$); tumor angiogenesis, multiple sclerosis, neurological disorders, asthma, vascular injury or diabetic

20

25


30

retinopathy ($\alpha v\beta 3$ or $\alpha v\beta 5$); and, angiogenesis (dual $\alpha v\beta 3/\alpha v\beta 5$) (S. A. Mousa, et al., *Emerging Therapeutic Targets*, **2000**, 4, (2), 148-149; W. H. Miller, et al., *Drug Discovery Today* **2000**, 5 (9), 397-407; and, S. A. Mousa, et al., *Exp. Opin. Ther. Patents*, **1999**, 9 (9), 1237-1248). The $\beta 3$ subunit has received
5 significant attention in recent drug discovery efforts. (W. J. Hoekstra, *Current Medicinal Chemistry* **1998**, 5, 195) and antibodies and/or low-molecular weight compound antagonists of $\alpha v\beta 3$ have shown efficacy in animal models (J. Samanen, *Current Pharmaceutical Design* **1997**, 3, 545).

10 Furthermore, GPIIb/IIIa and $\alpha v\beta 3$ antagonists have typically been designed after the bioactive arginine-glycine-aspartate (RGD) conformations of peptides derived from their primary ligands, fibrinogen and vitronectin, respectively. The RGD motif is the general cell attachment sequence of many
15 extracellular matrix, blood, and cell surface proteins, as half of the ca. 20 known integrins bind the RGD-containing adhesion ligands. To discover RGD peptides with integrin selectivity, peptides with both restricted conformations and alterations of flanking residues have been studied. In particular, the structural requirements for interaction of the RGD sequence with GPIIb/IIIa and the inhibitory potential of a series of nonpeptidic mimetics on platelet
20 aggregation and interactions with the extracellular matrix have been described (D. Varon, et al., *Thromb. Haemostasis*, **1993**, 70(6), 1030-1036). Iterative synthesis of cyclic and alicyclic peptides and computer modelling have provided potent, selective agents as a platform for nonpeptide αv integrin antagonist design.

25

For example, PCT Application WO98/25892 to Fisher, et al., describes a series of α -sulfonamido and α -sulfinamido carboxylic acid compounds of the formula:



wherein

Y is selected from the group consisting of $-\text{COOH}$, $-\text{PO}_3\text{H}_2$, $-\text{SO}_3\text{H}$ and $-\text{COOR}^4$; where R^4 is selected from the group consisting of $\text{C}_{1-10}\text{alkyl}$,

$\text{C}_{1-8}\text{alkylaryl}$, $\text{arylC}_{1-8}\text{alkyl}$, $\text{C}_{1-8}\text{alkyloxycarbonyloxyC}_{1-8}\text{alkyl}$,

5 $\text{aryloxycarbonyloxyC}_{1-8}\text{alkyl}$, $\text{C}_{1-8}\text{alkyloxycarbonyloxyaryl}$,

$\text{C}_{1-10}\text{alkylcarbonyloxyC}_{1-8}\text{alkyl}$ and $\text{C}_{1-8}\text{alkylcarbonyloxyaryl}$; A is selected from

the group consisting of $\text{C}_{6-12}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-NR}^5\text{-CO-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-O-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-NR}^5\text{-CO-C}_{1-8}\text{alkyl-NR}^5\text{-CO-C}_{0-8}\text{alkyl}$,

10 $\text{C}_{0-8}\text{alkyl-NR}^5\text{-CO-C}_{1-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{1-8}\text{alkyl-NR}^5\text{-CO-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-CO-C}_{1-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-CO-C}_{0-8}\text{alkyl-NR}^5\text{-CO-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-O-C}_{2-8}\text{alkyl-NR}^5\text{-CO-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-O-C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$,

15 $\text{C}_{0-8}\text{alkyl-O-C}_{2-8}\text{alkyl-O-C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-S-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-S(O}_n\text{)-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-S-C}_{2-8}\text{alkyl-NR}^5\text{-CO-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-S(O}_n\text{)-C}_{2-8}\text{alkyl-NR}^5\text{-CO-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-S-C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-S(O}_n\text{)-C}_{1-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-NR}^5\text{-CO-C}_{0-8}\text{alkyl-S-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-NR}^5\text{-CO-C}_{1-8}\text{alkyl-S(O}_n\text{)-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{2-8}\text{alkyl-S-C}_{0-8}\text{alkyl}$,

20 $\text{C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{2-8}\text{alkyl-S(O}_n\text{)-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-NR}^5\text{-C}_{0-8}\text{alkyl-CO}_2\text{-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-NR}^5\text{-C}_{0-8}\text{alkyl-CS-O-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-NR}^5\text{-C}_{0-8}\text{alkyl-CO-NR}^5\text{-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-NR}^5\text{-C}_{0-8}\text{alkyl-CS-NR}^5\text{-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-O-C}_{0-8}\text{alkyl-CO}_2\text{-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-O-C}_{0-8}\text{alkyl-CS-O-C}_{0-8}\text{alkyl}$, $\text{C}_{0-8}\text{alkyl-SiR}^7\text{R}^8\text{-C}_{0-8}\text{alkyl}$,

$\text{C}_{0-8}\text{alkyl-SiR}^7\text{R}^8\text{-C}_{0-8}\text{alkyl-NR}^6\text{-CO-C}_{0-8}\text{alkyl}$ and

25 $\text{C}_{0-8}\text{alkyl-SiR}^7\text{R}^8\text{-C}_{0-8}\text{alkyl-CO-NR}^6\text{-C}_{0-8}\text{alkyl}$; where R^5 , R^6 , R^7 and R^8 are

independently selected from the group consisting of H and $\text{C}_{1-6}\text{alkyl}$; and where

$n=1$ or 2 ; Z is selected from the group consisting of $-\text{NH-C(NR}^9\text{R}^{10})=\text{R}^{11}$,

$-\text{NH-C(R}^9)=\text{R}^{11}$, $-\text{C(NR}^9\text{R}^{10})=\text{R}^{11}$ and piperidinyl; where R^9 , R^{10} and R^{11} are

independently selected from the group consisting of H, $\text{C}_{1-6}\text{alkyl}$, $\text{arylC}_{1-3}\text{alkyl}$

30 and aryl; or where two of the R^9 , R^{10} or R^{11} substituents form a cyclic ring

containing $(\text{CH}_2)_p$, where $p=2-5$; R_1 is H and R_2 is selected from the group

consisting of $-\text{SO}_m\text{-aryl-}$, $-\text{SO}_m\text{-C}_{1-10}\text{alkyl-}$, $-\text{SO}_m\text{-heteroaryl-}$, where $m=1-2$; R^3 is


selected from the group consisting of H, $\text{C}_{1-8}\text{alkyl}$, aryl, $\text{C}_{1-8}\text{alkylaryl}$ and

heteroaryl as inhibitors of RGD-dependent integrins for the treatment of thrombotic or restenotic disorders.

Accordingly, it is an object of the present invention to provide compounds that are antagonists of integrins. It is another object to provide isonipecotamide compounds that are $\alpha v \beta 3$, $\alpha v \beta 5$, GPIIb/IIIa, dual $\alpha v \beta 3$ /GPIIb/IIIa or dual $\alpha v \beta 3/\alpha v \beta 5$ integrin antagonists. It is a further object to provide methods for treating a variety of integrin-mediated disorders including, but not limited to, unstable angina, thromboembolic disorders, atherosclerosis, arterial and/or venous thrombosis, restenosis, rheumatoid arthritis, vaso-occlusive disorders, osteoporosis, tumor angiogenesis, multiple sclerosis, neurological disorders, asthma, vascular injury, macular degeneration or diabetic complications including diabetic retinopathy.

Summary of the Invention

The present invention is directed to compounds represented by the following general Formula (I):



wherein

M is selected from C_1 - C_4 alkylene (optionally substituted within the carbon chain with one substituent selected from C_1 - C_4 alkyl, C_2 - C_4 alkenyl, cycloalkyl (wherein a ring carbon atom forms the point of attachment to the carbon chain) or aryl (optionally substituted with halogen) and substituted on the terminal carbon with one substituent selected from A), C_2 - C_4 alkenylene (substituted with one substituent selected from A), heterocyclylene (optionally substituted with one substituent selected from A), heterocyclenylene (substituted with one substituent selected from A), arylene (substituted with one substituent selected from A), (C_1 - C_4

alkylene)aryl (substituted on C₁-C₄ alkylene with one substituent selected from A) or arylene(C₁-C₄)alkyl (substituted on arylene with one substituent selected from A);

- 5 A is optionally present and is selected from heteroaryl, heterocyclyl, R₃HN-, (heteroaryl)amino, (heterocyclyl)amino, R₃HNC(=NH)-, R₃HNC(=NH)NH-, R₃HNC(=O)NH-, R₃C(=NH)NH-, (heterocyclyl)aminooxy, (heteroaryl)aminooxy, R₃HNC(=NH)NHO-, R₃C(=NH)NHO-, R₃HNC(=NH)NHC(=O)- or R₃C(=NH)NHC(=O)-; wherein heteroaryl and
- 10 heterocyclyl are optionally substituted with one to five substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, heteroaryl (optionally substituted with C₁-C₄ alkyl), halogen, hydroxy, nitro, cyano, trihalo(C₁-C₄)alkyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxycarbonyl, aryl(C₁-C₄)alkoxycarbonyl, R₃HN-, amino(C₁-C₄)alkyl, C₁-C₄
- 15 alkylamino(C₁-C₄)alkyl or di(C₁-C₄ alkyl)amino(C₁-C₄)alkyl;

with the proviso that if A is H₂NC(=NH)NH-, then, dependently, W is not hydrogen when Q is -CH₂-;

- 20 L is selected from -C(=O)-, -SO₂-, -OC(=O)- or -HNC(=O)-;

R₁ is selected from hydrogen, C₁-C₈ alkyl or cycloalkyl;

R₂ is selected from hydrogen or C₁-C₈ alkyl;

25

R₃ is selected from hydrogen, C₁-C₈ alkyl, aryl, aryl(C₁-C₈)alkyl, cycloalkyl, hydroxy, cyano or nitro;

- Q is selected from -CH₂-, -CH(C₁-C₈alkyl)-, -CH(C₂-C₈alkenyl)-, -CH(C₂-C₈alkynyl)-, -CH(aryl)- (wherein aryl is optionally substituted with one to five substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, -O-(C₁-C₃ alkyl)-O-, halogen, hydroxy, trihalo(C₁-C₃)alkyl or trihalo(C₁-C₃)alkoxy), -CH(heteroaryl)- (wherein heteroaryl is optionally
- 30

substituted with a substituent selected from halogen, hydroxy, C₁-C₄ alkyl, C₁-C₄ alkoxy, -O-(C₁-C₃ alkyl)-O-, amino, C₁-C₄ alkylamino or di(C₁-C₄)alkylamino or -CH(aryl(C₁-C₈)alkyl)-;

5 W is selected from hydrogen or N(R₄)T;

r is an integer selected from 0 or 1;

R₄ is selected from hydrogen, C₁-C₈ alkyl or C₂-C₆ acyl;

10

T is selected from R₅C(=O)-, R₅OC(=O)- or R₅C(=N-CN)-;

R₅ is selected from C₁-C₈ alkyl, aryl, aryl(C₁-C₈)alkyl or amino (wherein amino is optionally substituted with one to two substituents independently selected from C₁-C₈ alkyl);

15

R₆ is selected from hydrogen, C₁-C₈ alkyl, aryl(C₁-C₈)alkyl, (R₇)N(C₁-C₈)alkyl, (R₈)(R₇)N(C₁-C₈)alkyl or (R₈)(R₇)NC(=O)(C₁-C₈)alkyl; and,

20 R₇ and R₈ are independently selected from hydrogen, C₁-C₈ alkyl or cycloalkyl;

and pharmaceutically acceptable salts thereof.

25 Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above. Illustrating the invention is a pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier. An illustration of the invention is a process for making a
30 pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.

An example of the invention is a method of treating integrin-mediated disorders in a subject in need thereof comprising administering to the subject a

therapeutically effective amount of any of the compounds or pharmaceutical compositions described above. Examples of integrin-mediated disorders include, but are not limited to, unstable angina, thromboembolic disorders, atherosclerosis, arterial and/or venous thrombosis, restenosis, rheumatoid arthritis, vaso-occlusive disorders, osteoporosis, tumor angiogenesis, multiple sclerosis, neurological disorders, asthma, vascular injury, macular degeneration or diabetic complications, including diabetic retinopathy.

Further exemplifying the invention is the method of treating integrin-mediated disorders, wherein the therapeutically effective amount of the compound is from about 0.01 mg/kg/day to about 300 mg/kg/day.

Also included in the invention is the use of a compound of Formula (I) for the preparation of a medicament for treating an integrin-mediated disorder in a subject in need thereof.

The isonipecotamide compounds of the present invention are integrin antagonists; particularly, $\alpha v \beta 3$, $\alpha v \beta 5$, GPIIb/IIIa, dual $\alpha v \beta 3$ /GPIIb/IIIa and dual $\alpha v \beta 3$ / $\alpha v \beta 5$ integrin antagonists. The instant compounds are useful in treating thrombotic disorders such as restenosis, arterial and venous thrombosis, acute myocardial infarction, re-occlusion following thrombolytic therapy and angioplasty, inflammation, unstable angina, atherosclerosis, angiogenesis and a variety of vaso-occlusive disorders. These compounds are also useful as antithrombotics used in conjunction with fibrinolytic therapy (e.g., t-PA or streptokinase). Additionally, the compounds are useful in treating and preventing osteoporosis, rheumatoid arthritis, bone resorption, cancer, macular degeneration, and diabetic complications including diabetic retinopathy.

Detailed Description of the Invention

Relative to the above generic description, certain compounds of Formula (I) are preferred.

The preferred embodiments of the present invention are those

compounds wherein, independently,

M is selected from ethylene (optionally substituted within the carbon chain with methyl and substituted on the terminal carbon with one substituent selected from A), propylene (optionally substituted within the carbon chain with methyl, ethenyl, cyclohexylidene (wherein a ring carbon atom forms the point of attachment to the carbon chain) or 4-Cl-phenyl and substituted on the terminal carbon with one substituent selected from A), allylene (substituted with one substituent selected from A); piperidin-4-ylene (optionally substituted with one substituent selected from A), 1,4,5-dihydro-2-cyclopenten-1-ylene (substituted with one substituent selected from A) or 4-methylenepheryl (substituted on methylene with one substituent selected from A);

A is optionally present and is selected from 1*H*-imidazol-1-yl, 1*H*-imidazol-2-yl, 4,5-dihydro-1*H*-imidazol-2-yl (optionally substituted with a substituent selected from C₁-C₄ alkoxycarbonyl or aryl(C₁-C₄)alkoxycarbonyl), pyridin-2-yl (optionally substituted with a substituent selected from C₁-C₄ alkyl, heteroaryl (optionally substituted with C₁-C₄ alkyl), halogen, hydroxy, nitro, cyano, amino, amino(C₁-C₄)alkyl, C₁-C₄ alkylamino(C₁-C₄)alkyl or di(C₁-C₄ alkyl)amino(C₁-C₄)alkyl), pyrimidin-2-yl, 1,4,5,6-tetrahydro-pyrimidin-2-yl (optionally substituted with one to two substituents independently selected from C₁-C₄ alkyl, hydroxy or amino), piperidin-4-yl, benzimidazol-2-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-7-yl, 3*H*-imidazo[4,5-*b*]pyridin-2-yl, amino, (C₁-C₆ alkyl)amino, (1*H*-imidazol-1-yl)amino, (1*H*-imidazol-2-yl)amino, (4,5-dihydro-1*H*-imidazol-2-yl)amino (optionally substituted on 4,5-dihydro-1*H*-imidazol-2-yl with a substituent selected from C₁-C₆ alkoxycarbonyl or aryl(C₁-C₆)alkoxycarbonyl), (pyridin-2-yl)amino (optionally substituted on pyridin-2-yl with a substituent selected from C₁-C₄ alkyl, heteroaryl [optionally substituted with C₁-C₄ alkyl], halogen, hydroxy, nitro, cyano, amino, amino(C₁-C₄)alkyl, C₁-C₄ alkylamino(C₁-C₄)alkyl or di(C₁-C₄ alkyl)amino(C₁-C₄)alkyl), (pyrimidin-2-yl)amino, (1,4,5,6-tetrahydro-pyrimidin-2-yl)amino (optionally substituted on 1,4,5,6-tetrahydro-pyrimidin-2-yl with one to two substituents independently selected from C₁-C₄ alkyl,

hydroxy or amino), (4,5,6,7-tetrahydro-1*H*-1,3-diazepin-2-yl)amino, (thiazol-2-yl)amino, (benzimidazol-2-yl)amino, (3*H*-imidazo[4,5-*b*]pyridin-2-yl)amino, $R_3HNC(=NH)NH-$, $R_3HNC(=O)NH-$, (4,5,6,7-tetrahydro-1*H*-1,3-diazepin-2-yl)aminooxy, (4,5-dihydro-1*H*-imidazol-2-yl)aminooxy or $R_3HNC(=NH)NHO-$;

5

more preferably, A is optionally present and is selected from 1*H*-imidazol-1-yl, 4,5-dihydro-1*H*-imidazol-2-yl, pyridin-2-yl (optionally substituted with a substituent selected from C_1-C_4 alkyl or heteroaryl [optionally substituted with C_1-C_4 alkyl]), piperidin-4-yl, benzimidazol-2-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-7-yl, 3*H*-imidazo[4,5-*b*]pyridin-2-yl, amino, (4,5-dihydro-1*H*-imidazol-2-yl)amino (optionally substituted on 4,5-dihydro-1*H*-imidazol-2-yl with C_1-C_6 alkoxy carbonyl), (pyridin-2-yl)amino (optionally substituted on pyridinyl with a substituent selected from C_1-C_4 alkyl or heteroaryl [optionally substituted with C_1-C_4 alkyl]), (1,4,5,6-tetrahydro-5-hydroxypyrimidin-2-yl)amino, (1,4,5,6-tetrahydro-5-methylpyrimidin-2-yl)amino, (1,4,5,6-tetrahydro-5,5-dimethylpyrimidin-2-yl)amino, (thiazol-2-yl)amino, (3*H*-imidazo[4,5-*b*]pyridin-2-yl)amino, $R_3HNC(=NH)NH-$, $R_3HNC(=O)NH-$, (4,5-dihydro-1*H*-imidazol-2-yl)aminooxy or $R_3HNC(=NH)NHO-$;

10

15

20

25

most preferably, A is optionally present and is selected from 4,5-dihydro-1*H*-imidazol-2-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-7-yl, 3*H*-imidazo[4,5-*b*]pyridin-2-yl, amino, (4,5-dihydro-1*H*-imidazol-2-yl)amino, (pyridin-2-yl)amino, (3-methylpyridin-2-yl)amino, (thiazol-2-yl)amino, (3*H*-imidazo[4,5-*b*]pyridin-2-yl)amino, $NH_2C(=NH)NH-$, $R_3HNC(=O)NH-$, (4,5-dihydro-1*H*-imidazol-2-yl)aminooxy or $NH_2C(=NH)NHO-$,

with the proviso that if A is $H_2NC(=NH)NH-$, then, dependently, W is not hydrogen when Q is $-CH_2-$;

30

L is selected from $-C(=O)-$, $-OC(=O)-$ or $-HNC(=O)-$;

R_1 is selected from hydrogen or C_1-C_4 alkyl;

more preferably, R_1 is hydrogen;

R₂ is hydrogen;

R₃ is selected from hydrogen, C₁-C₈ alkyl, aryl(C₁-C₈)alkyl or hydroxy;

5 more preferably, R₃ is selected from hydrogen, butyl, benzyl or hydroxy;

Q is selected from -CH₂-, -CH(C₁-C₈alkyl)-, -CH(aryl)- (wherein aryl is optionally substituted with one to five substituents independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, -O-(C₁-C₃ alkyl)-O-, halogen, hydroxy or
 10 trihalo(C₁-C₃)alkyl), -CH(heteroaryl)- (wherein heteroaryl is optionally substituted with a substituent selected from halogen) or
 -CH(aryl(C₁-C₈)alkyl)-;

more preferably, Q is selected from -CH₂-, -CH(methyl)-, -CH(ethyl)-,

15 -CH(phenyl)- (wherein phenyl is optionally substituted with one to five substituents independently selected from methyl, ethyl, propyl, methoxy, ethoxy, propoxy, bromine, chlorine, fluorine, iodine, hydroxy or trifluoromethyl), -CH(naphthalen-1-yl)-, -CH(naphthalen-2-yl)-,
 -CH[(3,4-dioxymethylene)phenyl]-, -CH[(3,4-dioxyethylene)phenyl]-, -CH[(3-
 20 bromo-5-chloro-2-hydroxy)phenyl]-, -CH(thien-3-yl)-, -CH(quinolin-3-yl)-,
 -CH(pyridin-3-yl)- (wherein pyridinyl is optionally substituted with chlorine)
 or -CH(benzyl)-;

most preferably, Q is selected from -CH₂-, -CH(methyl)-, -CH(phenyl)- (wherein
 25 phenyl is optionally substituted with one to five substituents independently selected from methyl, methoxy, bromine, chlorine, fluorine, hydroxy or trifluoromethyl), -CH(naphthalen-1-yl)-, -CH(naphthalen-2-yl)-,
 -CH[(3,4-dioxymethylene)phenyl]-, -CH[(3,4-dioxyethylene)phenyl]-, -CH[(3-
 bromo-5-chloro-2-hydroxy)phenyl]-, -CH(thien-3-yl)-, -CH(quinolin-3-yl)-,
 30 -CH(pyridin-3-yl)- (wherein pyridinyl is optionally substituted with chlorine)
 or -CH(benzyl)-;

r is 1;

R_4 is selected from hydrogen or C_1 - C_4 alkyl;
more preferably, R_4 is hydrogen;

- 5 T is selected from $R_5C(=O)-$ or $R_5OC(=O)-$;
more preferably, T is selected from $R_5OC(=O)-$;


- R_5 is selected from aryl or aryl(C_1 - C_4)alkyl;
more preferably, R_5 is selected from aryl(C_1 - C_4)alkyl;
10 most preferably, R_5 is benzyl;

R_6 is selected from hydrogen, methyl or $(R_8)(R_7)NC(=O)CH_2$;
more preferably, R_6 is hydrogen;


- 15 R_7 and R_8 are independently selected from hydrogen, methyl or ethyl; and,
more preferably, R_7 and R_8 are independently ethyl;

and pharmaceutically acceptable salts thereof.


- 20 Exemplifying the invention is a compound of Formula (I) selected from:




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




32




33




34




35




36




37




38




39




40




41




42




43




44




45




46




47




48




49




50




51




52




53




54




55




56




57





58



59



60

**61, or****62**

and pharmaceutically acceptable salts thereof.

Particularly preferred compounds of Formula (I) are selected from:

Cpd	Name
1	β -[[[1-[4-[(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)amino]-1-oxobutyl]-4-piperidiny]carbonyl]amino]-, (β^3S)- 3-quinolinepropanoic acid;
2	3-[[[1-[4-[(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)amino]-1-oxobutyl]-4-piperidiny]carbonyl]amino]- <i>N</i> -[(phenylmethoxy)carbonyl]- L-alanine;
6	β -[[[1-[1-oxo-4-(2-pyridinylamino)butyl]-4-piperidiny]carbonyl]amino]-, (β^3S)- 3-quinolinepropanoic acid;
11	3-[[[1-[[1-(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)-4-piperidiny]carbonyl]-4-piperidiny]carbonyl]amino]- <i>N</i> -[(phenylmethoxy)carbonyl]- L-alanine;
14	3-[[[1-[[[1 <i>S</i> ,4 <i>R</i>]-4-[(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)amino]-2-cyclopenten-1-yl]carbonyl]-4-piperidiny]carbonyl]amino]- <i>N</i> -[(phenylmethoxy)carbonyl]- L-alanine;
16	3-[[[1-[3-[(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)amino]-2-methyl-1-oxopropyl]-4-piperidiny]carbonyl]amino]- <i>N</i> -[(phenylmethoxy)carbonyl]- L-alanine;
17	3-[[[1-[[[1 <i>R</i> ,4 <i>S</i>]-4-[(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)amino]-2-cyclopenten-1-yl]carbonyl]-4-piperidiny]carbonyl]amino]- <i>N</i> -[(phenylmethoxy)carbonyl]- L-alanine;
28	4-[[[(2 <i>S</i>)-2-carboxy-2-[[[(phenylmethoxy)carbonyl]amino]ethyl]amino]carbonyl]-, 2-[(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)amino]ethyl ester 1-piperidinecarboxylic acid;
39	β -[[[1-[2-[(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)amino]ethoxy]carbonyl]-4-piperidiny]carbonyl]amino]-, (β^3S)- 3-quinolinepropanoic acid;
47	3-[[[1-[4-[(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)amino]-2-methyl-1-oxobutyl]-4-piperidiny]carbonyl]amino]- <i>N</i> -[(phenylmethoxy)carbonyl]- L-alanine;

- 50 3-[[[1-(4-amino-1-oxo-5-hexenyl)-4-piperidiny]carbonyl]amino]-*N*-
[(phenylmethoxy)carbonyl]- L-alanine;
- 53 3-[[[1-[4-[[[4,5-dihydro-1*H*-imidazol-2-yl)amino]methyl]benzoyl]-4-
piperidiny]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
- 61 β -[[[1-[3-[[[4,5-dihydro-1*H*-imidazol-2-yl)amino]oxy]-1-oxopropyl]-4-
piperidiny]carbonyl]amino]- 1,3-benzodioxole-5-propanoic acid;
or,
- 62 β -[[[1-[1-oxo-4-(2-pyridinylamino)butyl]-4-piperidiny]carbonyl]amino]-
1,3-benzodioxole-5-propanoic acid;

and pharmaceutically acceptable salts thereof.

Representative Chemical Abstracts Service (CAS) Index-like names for
5 the compounds of the present invention were derived using the ACD/LABS
SOFTWARE™ Index Name Pro Version 4.0 nomenclature software program
provided by Advanced Chemistry Development, Inc., Toronto, Ontario,
Canada.

10 The compounds of the present invention may also be present in the
form of pharmaceutically acceptable salts. For use in medicine, the salts of the
compounds of this invention refer to non-toxic "pharmaceutically acceptable
salts." Other salts may, however, be useful in the preparation of compounds
according to this invention or of their pharmaceutically acceptable salts. The
15 pharmaceutically acceptable salts generally take a form in which a basic
nitrogen or nitrogens on the compound of the Formula (I) are protonated with
an inorganic or organic acid. Representative inorganic or organic acids
include, but are not limited to, hydrochloric, hydrobromic, hydriodic, perchloric,
sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic,
20 fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic,
hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-
naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic,
saccharinic or trifluoroacetic acid. Similarly, pharmaceutically acceptable salts
also include compounds wherein a carboxylic acid group of the compound of
25 the Formula (I) combines with a organic or inorganic base. Representative
inorganic or organic bases include, but are not limited to lithium, sodium,

potassium, magnesium, calcium, aluminum, zinc, benzathine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (*N*-methyl glucamine), tromethamine (2-amino-2-(hydroxymethyl)-1,3-propanediol) or procaine (4-amino-[2-(diethylamino)ethyl ester] benzoic acid).

5

As used herein, unless otherwise noted alkyl and alkoxy when used alone include straight and branched chains having 1 to 8 carbon atoms, or any number within this range. Similarly, alkenyl and alkynyl groups include straight and branched chain alkenes and alkynes having 2 to 8 carbon atoms, or any number within this range. The term alkylene, alkenylene and alkynylene refers to alkyl, alkenyl and alkynyl chains, respectively, that are further substituted and act as linking groups. Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups. Cycloalkyl groups contain 3 to 8 ring carbons; preferably, 5 to 8 ring carbons; and, more preferably, 5 to 7 ring carbons.

15

The term "heterocyclyl" as used herein refers to an optionally substituted, stable, saturated 3 to 10 (preferably 4 to 8) membered monocyclic or bicyclic ring system which consists of carbon atoms and from one to three heteroatoms selected from N, O or S. The term "heterocyclenyl" as used herein refers to an optionally substituted, stable, unsaturated 3 to 10 (preferably 4 to 8) membered monocyclic or bicyclic ring system which consists of carbon atoms and from one to three heteroatoms selected from N, O or S. The heterocyclyl or heterocyclenyl group may be attached at any heteroatom or carbon atom which results in the creation of a stable structure and, accordingly, may be further attached to, for example, alkyl or alkoxy chains. The term heterocyclylene and heterocyclenylene refers to heterocyclyl and heterocyclenyl groups, respectively, that are further substituted and act as linking groups; wherein, one or both rings may be optionally substituted with one to five substituents attached at any heteroatom or carbon atom which results in the creation of a stable structure.

25

30

The term "aryl", as used herein, refers to optionally substituted aromatic

groups such as phenyl and naphthyl. The term arylene refers to aryl groups that are further substituted and act as linking groups; wherein, one or both rings may be optionally substituted with one to five substituents attached at any carbon atom which results in the creation of a stable structure.

5

The term "heteroaryl" as used herein represents a stable five or six membered monocyclic aromatic ring system or a nine or ten membered benzo-fused heteroaromatic ring system which consists of carbon atoms and from one to three heteroatoms selected from N, O or S. The heteroaryl group may be attached or optionally substituted at any heteroatom or carbon atom which results in the creation of a stable structure.

10

The term "arylalkyl" means an alkyl group substituted with an aryl group (e.g., benzyl, phenethyl). Similarly, the term "arylalkoxy" indicates an alkoxy group substituted with an aryl group (e.g., benzyloxy).

15

The term "acyl" as used herein means an organic radical having 2 to 6 carbon atoms (branched or straight chain) derived from an organic acid by removal of the hydroxy group.

20

Whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., aralkyl, alkylamino) it shall be interpreted as including those limitations given above for "alkyl" and "aryl." When present, designated numbers of carbon atoms (e.g., C₁-C₈) shall refer independently to the number of carbon atoms in a moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.

25


Any of the foregoing cycloalkyl, heterocyclyl, heterocyclenyl, aryl and heteroaryl substituent groups and their corresponding heterocyclylene, heterocyclenylene, arylene and heteroarylene linking groups, as a monocyclic or bicyclic ring system may be further bridged at any heteroatom or carbon atom which results in the creation of a stable ring structure; wherein the monocyclic bridged ring system consists of 6 to 8 members and the bicyclic

30

bridged ring system consists of 10 to 12 members.

It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.

Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. Thus, for example, a "phenylC₁-C₆ alkylamidoC₁-C₆alkyl" substituent refers to a group of the formula:



The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible *in vivo* into the required compound. Examples of prodrugs include but are not limited to various esters, hydroxyamidines and hydroxyguanidines of compounds of the present invention. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound *in vivo* after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

The term "bone resorption," as used herein, refers to the process by which osteoclasts degrade bone.

The present invention provides isonipecotamide compounds that are useful as $\alpha v\beta 3$, $\alpha v\beta 5$ and GPIIb/IIIa integrin antagonists. Compounds of Formula (I) that are particularly preferred as $\alpha v\beta 3$ integrin antagonists are selected from Compound 1, 2, 3, 5, 6, 12, 14, 16, 18, 21, 24, 25, 28, 29, 31, 33, 34, 39, 40, 44, 47, 49, 54, 55, 58 or 60. Compounds of Formula (I) that are particularly preferred as GPIIb/IIIa integrin antagonists are selected from Compound 1, 2, 5, 11, 12, 14, 16, 17, 18, 19, 39, 47, 49, 50, 53, 54, 55 or 56. Compounds of Formula (I) that are particularly preferred as $\alpha v\beta 5$ integrin antagonists are selected from Compound 1, 2, 16, 45, 58 or 60. Compounds

of Formula (I) that are particularly preferred as dual $\alpha v\beta 3$ /GPIIb/IIIa integrin antagonists are selected from Compound **2, 5, 12, 14, 16, 18, 39, 47, 49, 54** or **55**. Compounds of Formula (I) that are particularly preferred as dual $\alpha v\beta 3/\alpha v\beta 5$ integrin antagonists are selected from Compound **1, 2, 16, 58** or **60**.

5

Compounds of Formula (I) that are more particularly preferred as $\alpha v\beta 3$ integrin antagonists are selected from Compound **1, 2, 6, 28, 39** or **47**.

Compounds of Formula (I) that are more particularly preferred as GPIIb/IIIa integrin antagonists are selected from Compound **2, 11, 14, 17, 50** or **53**.

10 Compounds of Formula (I) that are more particularly preferred as $\alpha v\beta 5$ integrin antagonists are selected from Compound **1, 2** or **16**. Compounds of Formula (I) that are more particularly preferred as dual $\alpha v\beta 3$ /GPIIb/IIIa integrin antagonists are Compound **2**. Compounds of Formula (I) that are more particularly preferred as dual $\alpha v\beta 3/\alpha v\beta 5$ integrin antagonists are selected from
15 Compound **1** or **2**.

The compounds of Formula (I) inhibit the binding of adhesive proteins such as fibrinogen, vitronectin, and osteopontin to the integrin class of receptors. As demonstrated by the results of the biological studies described
20 hereinafter, the compounds block vitronectin binding to isolated $\alpha v\beta 3$ (IC_{50} 's of ca. 1-300 nM), and inhibit fibrinogen binding to isolated GPIIb/IIIa as well. Because the compounds of this invention inhibit integrin-mediated cell-cell or cell-matrix adhesion, they may be useful against restenosis, thrombosis, inflammation, atherosclerosis, arthritis, angiogenesis, osteoporosis, bone
25 resorption, tumor cell metastasis, tumor growth, macular degeneration, diabetic retinopathy, diseases of lung/airway resistance, etc. (D. Cox, *Drug News & Perspectives* **1995**, 8, 197).

The compounds of Formula (I) are also useful as antithrombotics in
30 combination with fibrinolytic therapy (e.g., t-PA or streptokinase). Additionally, the compounds of Formula (I) are useful in combination with one or more agents useful in the prevention or treatment of osteoporosis and arthritis. For

example, the compounds of the instant invention may be effectively administered in combination with other agents used in the treatment of osteoporosis such as bisphosphonate bone resorption inhibitors; preferably, the bisphosphonate bone resorption inhibitor is alendronate, sold as
5 FOSAMAX®. Preferred combinations are simultaneous or alternating treatments of an integrin antagonist of the present invention and alendronate.

In accordance with the methods of the present invention, the individual components of the combination can be administered separately at different
10 times during the course of therapy or concurrently in divided or single combination forms. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.

15 As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

20 The utility of the compounds to treat integrin-mediated disorders can be determined according to the procedures herein. The present invention therefore provides a method of treating integrin-mediated disorders in a subject in need thereof which comprises administering any of the compounds as defined herein in a quantity effective to treat thrombotic disorders,
25 osteoporosis, cancer, and diabetic complications. The compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal and parenteral.

30 The present invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier.

To prepare the pharmaceutical compositions of this invention, one or more compounds of Formula (I) or salt thereof of the invention as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above.

The pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.01 mg/kg to 100 mg/kg (preferably, from about 0.1 mg/kg to about 30 mg/kg) and may be given at a dosage of from about 0.01 mg/kg/day to about 300 mg/kg/day (preferably, from about 1 mg/kg/day to about 50 mg/kg/day).

The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.

Preferably these compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of material can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

10

Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.

15

20

25

During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis; Third Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

30

The method of treating integrin-mediated disorders described in the present invention may also be carried out using a pharmaceutical composition comprising any of the compounds as defined herein and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain between about 0.01 mg and 100 mg, preferably about 5 to 50 mg, of the compound, and may be constituted into any form suitable for the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorings, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.

Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium

benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

5 The liquid forms in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.

10

 The compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or
15 phosphatidylcholines.

 Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with
20 soluble polymers as targeted drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxy-ethylaspartamidephenol, or polyethyl eneoxydepolylysine substituted with palmitoyl residue. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving
25 controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

30 Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of thrombotic disorders is required.

The daily dosage of the products may be varied over a wide range from about 0.01 mg to about 21,000 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A therapeutically effective amount of the drug is ordinarily supplied at a dosage level of from about 0.01 mg/kg to about 300 mg/kg of body weight per day. Preferably, the range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day; and more preferably, the range is from about 0.01 mg/kg to about 50 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.

20

Abbreviations used in the instant specification, particularly the Schemes and Examples, are as follows:

Aq.	=	aqueous
Bn or Bzl	=	benzyl
Boc	=	<i>tert</i> -butoxycarbonyl
Boc ₂ O	=	di- <i>tert</i> -butyl dicarbonate
BSA	=	bovine serum albumin
<i>n</i> -Bu	=	<i>n</i> -butyl
Cbz	=	benzyloxycarbonyl
CP or Cpd	=	Compound
DCM	=	dichloromethane
DIC	=	diisopropylcarbodiimide
DIPEA	=	diisopropylethylamine
DMAP	=	4-dimethylaminopyridine
DMF	=	N, N-dimethylformamide

DMSO	=	dimethylsulfoxide
EDC	=	ethyl dimethylaminopropyl-carbodiimide
EDTA	=	ethylenediaminetetraacetic acid
ES	=	electrospray
Et	=	ethyl
Et ₂ O	=	diethyl ether
EtOH	=	ethanol
¹ H NMR	=	proton nuclear magnetic resonance spectrum
HBTU	=	2-(1 <i>H</i> -benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HEPES	=	4-(2-hydroxyethyl)-1- piperazine-ethanesulfonic acid
HOBT	=	hydroxybenzotriazole
HBTU	=	2-(1 <i>H</i> -benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate
IPA	=	2-propanol
Me	=	methyl
MeOH	=	methanol
MH ⁺	=	observed molecular ion
MPK	=	milligrams per kilogram
MS	=	mass spectrum
NMM	=	N-methylmorpholine
NT	=	not tested
Ph	=	phenyl
PPT	=	precipitate
Pyr.	=	pyridine
RP-HPLC	=	preparative reversed-phase high pressure liquid chromatography
RT	=	room temperature
Sch	=	Scheme
TEA	=	triethylamine
THF	=	tetrahydrofuran
TFA	=	trifluoroacetic acid
TMS	=	trimethylsilane
Z	=	benzyloxycarbonyl

General Synthetic Methods

Although the following Schemes depict synthetic routes to specific
5 compounds of Formula (I), they are intended to also represent general
synthetic routes to other compounds of the present invention to those skilled in
the art of synthetic organic chemistry. By way of example, the synthetic route

shown in Scheme AA used to prepare Compound **1** is also illustrative of a general method for the preparation of other instant compounds whereby other starting materials and appropriate reagents and solvents are used. Most of the reaction unless otherwise indicated were performed at room temperature.

5

SCHEME AA

Compounds of the invention wherein A is (4,5-dihydro-1*H*-imidazol-2-yl)amino and its homologs may be prepared as shown below. The β -Aminoacid derivative **AA5** was prepared as detailed in PCT International Application WO 97/41102 and as published (J. Rico, *J. Org. Chem.* **1993**, 58, 7948). Such β -aminoacid derivatives can also be prepared by the methods described in WO 97/08145 and in U.S. Patent 6,100,423. The reagent **AA3** was purchased from Maybridge Chemical Company.

For the preparation of compounds exemplified by final target Compound **1**, secondary amine **AA1** was coupled with 4-*N*-Boc-aminobutyric acid in the presence, and the Boc group subsequently removed with trifluoroacetic acid to give primary amine **AA2** as the TFA salt. This salt was acylated with reagent **AA3**, the 2-aminoimidazoline product was protected with di-*tert*-butyl dicarbonate, and the methyl ester was saponified with lithium hydroxide to afford **AA4**. Intermediate **AA4** was coupled with amino ester **AA5** in the presence of HBTU, and the product was then de-protected with aqueous hydrochloric acid to give the target Compound **1**. Similarly, the Boc group of coupling product from **AA4** and **AA5** can be removed with a mixture of trifluoroacetic acid in dichloromethane (1:1) and the ester moiety subsequently saponified with aqueous LiOH in tetrahydrofuran to afford the lithium salt of Compound **1**. If the ester derivative is desired, then the saponification step is eliminated.

For the preparation of α -diaminoalkanoic acid derivative compounds of Formula (I), such as those exemplified by the Compound **11**, the secondary amine **AA1** was reacted with (N-*t*-butyloxycarbonyl)isonipecotic acid (purchased from BaChem) instead of 4-*N*-Boc-aminobutyric acid and the


product was carried forward to replace **AA2** in Scheme AA, wherein **AB2** was used to replace **AA5** to produce the target Compound **11**.

5 Similarly, for the preparation of compounds of Formula (I), such as those exemplified by Compound **16**, the secondary amine **AA1** was reacted with commercially available *N*-Boc-(3-amino-2-methyl)propionic acid instead of 4-*N*-Boc-aminobutyric acid and carried forward to replace **AA2** in Scheme AA, wherein **AB2** was used to replace **AA5** to produce the target Compound **16**.

10 For the preparation of compounds of Formula (I) exemplified by Compound **53**, the secondary amine **AA1** was reacted with the commercially available *N*-Boc-(4-aminomethyl)benzoic acid instead of 4-*N*-Boc-aminobutyric acid and carried forward to replace **AA2** in Scheme AA to produce the target Compound **53**.


15 For the preparation of compounds of Formula (I), such as those exemplified by Compound **14** and Compound **17**, the secondary amine **AA1** was reacted with commercially available (-)-(1*R*,4*S*)-*N*-Boc-1-aminocyclopent-2-ene-4-carboxylic acid (for Compound **14**) or (+)-(1*S*,4*R*)-*N*-Boc-1-aminocyclopent-2-ene-4-carboxylic acid (for Compound **17**) instead of 4-*N*-Boc-aminobutyric acid. The resulting product replaced **AA2** in Scheme AA and was carried forward, with **AB2** replacing **AA5**, to produce Compound **14** and Compound **17**, respectively.

20




SCHEME AB

- The α -diaminoalkanoic acid derivatives of Formula (I), such as
- 5 Compound 2, can be prepared from ester intermediates, such as the free base of **AB2** (methyl *N*- α -(benzyloxycarbonyl)-L-2,3-diaminopropionate), to replace **AA5** in Scheme AA. In this example, Cbz-protected acid **AB1** (purchased from BaChem) was dissolved in methanol and treated with 4N HCl in 1,4-dioxane in the presence of 1,2-dimethoxypropane to afford the intermediate amino ester
- 10 **AB2**. Using the method described in Scheme AA, the free base of **AB2** was used to replace **AA5** to produce Compound 2.




SCHEME AC

Compounds of Formula (I) wherein A is heteroaryl, heterocyclyl, (heteroaryl)amino or (heterocyclyl)amino, such as Compound **6**, can be prepared by reacting the heteroaryl, heterocyclyl, (heteroaryl)amino or (heterocyclyl)amino starting material with the appropriate alkyl halide. For example, Compound **AC1** was acylated with 4-bromobutyryl chloride. The resulting alkyl bromide product was reacted with (pyridin-2-yl)amino at reflux to provide **AC2**. The ester **AC2** was saponified with lithium hydroxide and carried forward to replace **AA4** in Scheme AA to give Compound **6**. Other compounds of Formula (I), such as Compounds **30**, **41** and **62**, can be prepared using Scheme AC by varying the starting material used.



Another method used to prepare heterocyclyl compounds, such as benzimidazol-2-yl, was the N-acylation of starting materials using methodology analogous to that shown in Scheme AA. For example, the N-acylation of **AC3** with **AD2** followed by saponification and deprotection by removal of the Boc group afforded Compounds **8**, **13** and **15**.




Certain other (heterocyclyl)amino compounds may be prepared by reacting a 2-fluoroheterocyclyl compound with the appropriate aminoalkanoate

(e.g., **AA2**) as reported by C. Senanayake in *Tetrahedron Lett.* **1999**, 40, 6875. For compounds where A is (tetrahydro-pyrimidin-2-yl)amino or (pyrimidin-2-yl)amino, 2-bromopyrimidine may be reacted with the appropriate aminoalkanoate (e.g., **AA2**) as reported by G. Hartman in WO 95/32710. For
5 compounds where A is 1*H*-imidazo[4,5*b*]pyridin-2-yl, an appropriate alkyl dicarboxylic acid (e.g., succinic acid) may be reacted with 2,3-diaminopyridine as reported by R. Keenan in *Bioorg. Med. Chem. Lett.* **1998**, 8, 3171.


SCHEME AD

10 Scheme AD provides an alternate method of synthesis for the α -diaminoalkanoic acid derivatives of Formula (I), such as Compound **2**, by changing the order of the coupling steps depicted in Scheme AA. For example, the isonipecotamide intermediate **AD2** used to further synthesize other α -diaminoalkanoic acid derivative compounds of the invention was
15 prepared by the HBTU-mediated coupling of **AD1** (purchased from Advanced Chemtech) and **AB2**.




20 The acid **AD3** was prepared (as described by J. V. Greenhill, *Chem. Soc., Perkin Trans. 2* **1985**, (8), 1255-1264) and was reacted with di-*tert*-butyl dicarbonate in the presence of NaOH. The intermediate sodium salt was coupled with **AD2** using HBTU to afford **AD4**. Deprotection of **AD4** with 4 M HCl (aq.) yielded Compound **2**.

25




SCHEME AE

Compounds of Formula (I) wherein A includes an aminooxy moiety can be prepared by the methods represented below. Boc-protected aminooxy intermediate **AE5** (used to prepare Compound **58**) and aminooxy intermediate **AE8** (used to prepare Compounds **60** and **61**) were synthesized according to the methods described by C. Gilon, et. al. in *Tetrahedron* **1967**, 23, 441-4447 and B. J. Ludwig in *J. Med. Chem.* **1970**, 13, 60-63. Commercially available β -propiolactone **AE1** and N-hydroxysuccinimide **AE2** were reacted to afford the corresponding oxyamino ester, which was hydrolyzed in a refluxing mixture of 6 M HCl (aq.) and glacial acetic acid. The resulting HCl salt was converted to the free base **AE3** by treatment with NaOMe in 2-propanol. Guanylation of **AE3** with commercially available **AE4** followed by reaction with di-*tert*-butyl dicarbonate furnished the protected oxyguanidine intermediate **AE5**. To produce the target Compound **53**, the secondary amine **AA1** in Scheme AA was reacted with the protected oxyguanidine intermediate **AE5** instead of 4-*N*-Boc-aminobutyric acid and carried forward as **AA2**.




Similarly, Boc-protection of **AE6** (purchased from Aldrich) produced **AE7**, followed by reaction of **AE7** with **AE3** to afford the protected (4,5-dihydro-1H-imidazol-2-yl)aminooxy intermediate **AE8**. To produce the target Compounds **60** and **61**, the secondary amine **AA1** in Scheme AA was reacted with the protected (4,5-dihydro-1H-imidazol-2-yl)aminooxy intermediate **AE8** instead of 4-N-Boc-aminobutyric acid and carried forward as **AA2**.




SCHEME AF

Compounds of Formula (I) wherein A includes a urea moiety, such as Compound **59**, may be prepared as depicted below. HBTU-mediated coupling of commercially available starting materials **AF1** and **AF2** and subsequent saponification of the intermediate ester furnished **AF3**, which was coupled with **AB2** to give **AF4**. Deprotection of **AF4** with TFA/DCM followed by reaction with phenyl isocyanate and hydrolysis of the resulting ester with 4 M HCl (aq.) yielded Compound **59**.




SCHEME AG

Compounds of the Formula (I) wherein A is (heterocyclyl)amino, may be prepared by reacting certain activated methylthio derivatives with the appropriate amine. For example, Compound **57** can be prepared by reacting **AG1** (purchased from Aldrich) with amine **AF4** followed by acid hydrolysis of the resulting ester.




Similarly, thiourea **AG2**, prepared as described in WO/0034255, is activated with methyl iodide followed by reaction with **AG3** as described in WO/9708145 to provide **AG4**.




SCHEME AH

Compounds of Formula (I) wherein L is -OC(=O)- or -HNC(=O)- can be prepared as outlined below. The protected aminoalcohol **AH1** can be converted to a corresponding *p*-nitrophenylcarbonate intermediate by reaction with **AH2**. Reaction of the *p*-nitrophenylcarbonate intermediate product with **AF1**, followed by removal of the Boc group furnished an amine intermediate. The amine intermediate was subsequently reacted with reagent **AA3** to give a corresponding (imidazolin-2-yl)amino intermediate. Boc protection of the (imidazolin-2-yl)amino intermediate followed by saponification yielded **AH3**, which was used to replace intermediate **AA4** in Scheme AA to produce Compounds **28, 29, 31, 35, 39** and **40**.




Similarly, **AD2** was converted to **AH4** by reaction with **AH2** to produce **AH4**. Reaction of **AH4** with **AH5** and saponification provided Compound **10**.



SCHEME AI

- Compounds of the Formula (I) wherein A is amino or R₃H₂N- can be prepared by coupling **AA1** with the appropriate Boc-protected amino acid, such as **AI1**, followed by saponification to give **AI2** as an intermediate. The intermediate **AI2** was coupled with **AB2**, then treated with aqueous HCl to yield Compound **50**. Similarly, Compound **56** was prepared by substituting 4-*N*-Boc-aminobutyric acid for **AI1**.



Specific Synthetic Methods

The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims which follow thereafter.

Protected amino acids were purchased from Bachem Bioscience Inc. *N*- α -Cbz-L-2,3-diaminopropionic acid was purchased from Fluka. Aromatic aldehydes were purchased from Aldrich Chemical Company, as were all other chemicals. High field ¹H NMR spectra were recorded on a Bruker AC-360 spectrometer at 360 MHz, and coupling constants are given in Hertz. Melting points were determined on a Mel-Temp II melting point apparatus and are uncorrected. Microanalyses were performed at Robertson Microlit Laboratories, Inc., Madison, New Jersey and are expressed in percentage by weight of each element per total molecular weight. In those cases where the product is obtained as a salt, the free base is obtained by methods known to those skilled in the art, e.g. by basic ion exchange purification. Nuclear magnetic resonance (NMR) spectra for hydrogen atoms were measured in the

indicated solvent with tetramethylsilane (TMS) as the internal standard on a Bruker AM-360 (360 MHz) spectrometer. The values are expressed in parts per million down field from TMS. The mass spectra (MS) were determined on a Micromass Platform LC single quadrupole mass analyser fitted with an electrospray ionisation source coupled to a Hewlett Packard 1050 HPLC and a Jones Chromatography diverter valve in the loop injection mode. Positive mode electrospray was used eluting with acetonitrile/water/acetic acid (50:50:1) flowing at 0.3 mL/min with a sprayer temperature of 120 °C and an inlet desolvation cone set to 40 kV.

Unless otherwise noted, the materials used in the examples were obtained from readily available commercial suppliers or synthesized by standard methods known to anyone skilled in the art of chemical synthesis. The substituent groups, which vary between examples, are hydrogen unless otherwise noted.

EXAMPLE 1

β -[[[1-[4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-1-oxobutyl]-4-piperidiny]carbonyl]amino]-, (β^3 S)-3-quinolinepropanoic acid (Cpd 1)

A mixture of **AA1** (2.0 g, HCl salt, 0.011 mol), CH₂Cl₂ (100 mL), 4-*N*-Boc-aminobutyric acid (2.3 g, 1 eq), NMM (2.4 mL, 2 eq), HOBT (10 mg), and EDC•HCl (3.2 g, 1.5 eq) was stirred at 5 °C for 1 h, the ice bath was removed, and stirred for 2 h. The reaction was diluted with saturated aqueous NH₄Cl (50 mL) and the layers were separated. The organic layer was washed with NaOH (0.5 N, 15 mL), dried (Na₂SO₄), and evaporated to give a glass (3.6 g, 0.011 mol). This glass was dissolved in CH₂Cl₂ (15 mL) and anisole (1 mL), treated with TFA (15 mL), and stirred for 2 h. The solution was evaporated to give an oil (**AA2**, 3.8 g). **AA2** was dissolved in dioxane (40 mL), treated with NMM (2.4 mL, 2 eq) and 2-(3,5-dimethylpyrazolyl)-4,5-dihydroimidazole•HBr **AA3** (2.7 g, 1 eq) and heated at reflux for 2 h. This mixture was cooled to RT and filtered. The filtrate was treated with MeOH (80 mL), NMM (2.4 mL, 2 eq), di-*tert*-butyl dicarbonate (4.8 g, 2 eq), and sodium carbonate (2.4 g, 2 eq), and stirred for 3

days. The solvents were evaporated, and the residue was partitioned between CH₂Cl₂ (100 mL) and water (10 mL). The organic layer was dried (Na₂SO₄), evaporated, and the oil purified by silica gel chromatography (1% NH₄OH/10% MeOH/CH₂Cl₂) to give a tan glass (1.8 g). The tan glass (0.09 g, 0.0023 mol) was dissolved in THF (5 mL), cooled to 5°C, treated with aqueous LiOH (0.11 g in 15 mL water), and stirred for 2 h. The solvents were evaporated to give **AA4** as a pale yellow solid (1.0 g). This solid was slurried with MeCN (100 mL), **AA5** (0.82 g, 1 eq, prepared starting from quinoline-3-carboxaldehyde as reported in M. Costanzo, et. al., WO 97/41102), HOBt (0.19 g, 0.5 eq), NMM (0.87 mL, 3 eq), and HBTU (1.2 g, 1.2 eq) at 5 °C, stirred for 6 h, diluted with saturated aqueous NH₄Cl (12 mL), and the MeCN evaporated. The residue was partitioned between CHCl₃ (100 mL) and water (15 mL) and filtered. The filtrate layers were separated, and the organic layer was dried (Na₂SO₄), evaporated, and purified by silica gel chromatography (1% NH₄OH/4% MeOH/7% EtOH/CH₂Cl₂) to give a clear glass (0.60 g). The glass was treated with water (12 mL) and HCl (conc., 10 mL), and stirred for 18 h. The aqueous HCl was evaporated, the resultant oil treated with MeCN (20 mL), and the precipitate collected and dried to afford Compound **1** as a white foam: ¹H NMR (DMSO-d₆) δ 1.3 (m, 2 H), 1.6 (m, 4 H), 2.3 (m, 2 H), 2.6 (m, 1 H), 2.8 (m, 1 H), 3.1 (m, 6 H), 3.4 (m, 1 H), 3.7 (m, 3 H), 3.8 (m, 1 H), 4.0 (m, 2 H), 4.2 (m, 1 H), 5.3 (m, 1 H), 7.7 (t, J = 4 Hz, 1 H), 7.9 (t, J = 4 Hz, 1 H), 8.2 (m, 2 H), 8.3 (m, 1 H), 8.6 (m, 2 H), 9.2 (s, 1 H), 10.9 (m, 1 H); MS m/e 481.4 (MH⁺); [α]_D²⁵ -42.1° (c 0.114, MeOH).

25

EXAMPLE 2

3-[[[1-[4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-1-oxobutyl]-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]-L-alanine (Cpd **2**)

Compound **2** was prepared as described for Compound **1** in Scheme AA using **AA4** (0.10 g) and methyl *N*-α-Cbz-L-2,3-diaminopropionate•HCl **AB2** to replace **AA5** (0.09 g), and isolated as a tan glass: ¹H NMR (DMSO-d₆) δ 1.3 (m, 1 H), 1.4 (m, 1 H), 1.7 (m, 4 H), 2.4 (m, 3 H), 2.6 (m, 2 H), 2.8 (t, J = 4 Hz, 1 H), 3.0 (m, 1 H), 3.1 (m, 1 H), 3.3 (m, 2 H), 3.4 (m, 1 H), 3.8 (m, 2 H), 4.1 (t, J

= 4 Hz, 1 H), 4.3 (m, 1 H), 5.0 (t, J = 7 Hz, 2 H), 7.3 (m, 5 H), 7.6 (m, 3 H), 8.0 (m, 3 H), 8.2 (m, 1 H); MS m/e 503.4 (MH⁺).

EXAMPLE 3

5 6-chloro-β-[[[1-[4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-
1-oxobutyl]-4-piperidiny]carbonyl]amino]-,
(β³S)-3-pyridinepropanoic acid (Cpd 3)

Compound 3 was prepared as described for Compound 1 in Scheme AA using **AA4** (0.15 g) and methyl (3*S*)-amino-3-(6-chloro-3-pyridyl)propionate•2HCl (0.11 g; prepared starting from 6-chloropyridine-3-carboxaldehyde as reported by M. Costanzo, et al. in WO 97/41102) for **AA5**, and isolated as a clear glass: ¹H NMR (DMSO-d₆) δ 1.2 (m, 4 H), 1.5 (m, 2 H), 2.2 (m, 3 H), 2.5 (m, 2 H), 2.7 (m, 2 H), 2.8 (m, 1 H), 3.1 (m, 1 H), 3.5 (m, 3 H), 3.8 (m, 1 H), 4.1 (m, 3 H), 4.3 (m, 1 H), 5.1 (m, 1 H), 7.4 (d, J = 5 Hz, 1 H), 7.7 (d, J = 5 Hz, 1 H), 8.1 (m, 3 H), 8.3 (s, 1 H), 8.5 (m, 1 H); MS m/e 464.9 (MH⁺).

EXAMPLE 4

3-[[[1-[4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-
1-oxobutyl]-4-piperidiny]carbonyl]amino]-,
20 (3*R*)- butanoic acid (Cpd 4)

Compound 4 was prepared as described for Compound 1 in Scheme AA using **AA4** (0.90 g) and *tert*-butyl (3*R*)-aminobutyrate (0.37 g, purchased from Oxford Asymmetry) for **AA5**, and isolated as a clear glass: ¹H NMR (DMSO-d₆) δ 1.0 (d, J = 5 Hz, 3 H), 1.3 (m, 2 H), 1.7 (m, 4 H), 2.3 (m, 6 H), 2.6 (m, 1 H), 3.0 (m, 1 H), 3.2 (m, 2 H), 3.6 (s, 4 H), 3.8 (m, 1 H), 4.0 (m, 1 H), 4.4 (m, 1 H), 7.8 (d, J = 7 Hz, 2 H), 8.2 (m, 2 H); MS m/e 368.4 (MH⁺).

EXAMPLE 5

β-[[[1-[3-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-2-methyl-
1-oxopropyl]-4-piperidiny]carbonyl]amino]-,
30 (β³S)-3-quinolinepropanoic acid (Cpd 5)

Compound 5 was prepared as described for Compound 1 in Scheme AA using *N*-Boc-imidazolin-2-yl-(3-aminoisobutyryl)-isonipecotic acid (0.10 g) for

AA4 and **AA5** (0.12 g), and isolated as glass: ^1H NMR (DMSO- d_6) δ 1.1 (d, J = 6 Hz, 3 H), 1.3 (m, 1 H), 1.4 (m, 1 H), 1.7 (m, 4 H), 2.3 (m, 2 H), 2.6 (m, 2 H), 2.8 (m, 1 H), 3.0 (m, 2 H), 3.1 (m, 1 H), 3.3 (m, 2 H), 3.4 (m, 1 H), 3.8 (m, 1 H), 4.1 (m, 1 H), 4.3 (m, 1 H), 5.0 (t, J = 7 Hz, 2 H), 7.3 (m, 5 H), 7.6 (m, 2 H), 8.0 (m, 3 H); MS m/e 503.4 (MH^+).

EXAMPLE 6

β -[[[1-[1-oxo-4-(2-pyridinylamino)butyl]-4-piperidiny]carbonyl]amino]-, ($\beta^3\text{S}$)- 3-quinolinepropanoic acid (Cpd 6)

A mixture of **AC1** (2.0 g, 0.011 mol), CH_2Cl_2 (70 mL), and NMM (2.4 mL, 2 eq) at 5 °C was treated with 4-bromobutyryl chloride (1.3 mL, 1 eq), stirred for 6 h, and diluted with saturated aqueous NH_4Cl (15 mL). The organic layer was dried (Na_2SO_4), evaporated, and the resultant oil purified by silica gel chromatography (4% MeOH/ CH_2Cl_2) to give an oil (1.8 g). The oil was dissolved in MeOH (10 mL) and isopropanol (15 mL) and then treated with 2-aminopyridine (0.70 g, 1.2 eq) and sodium carbonate (2 mg). This mixture was heated at reflux in a sealed flask for 2 h, cooled to RT, and evaporated to an oil. The oil was purified by silica gel chromatography (2% MeOH/3% EtOH/ CH_2Cl_2) to give **AC2** as a glass (0.3 g) intermediate. The intermediate **AC2** was then saponified with lithium hydroxide and carried forward to replace **AA4** as exemplified in Scheme AA to produce Compound 6 as clear flakes: ^1H NMR (DMSO- d_6) δ 1.0-1.2 (m, 2 H), 1.7 (m, 4 H), 2.2 (m, 2 H), 3.0 (m, 3 H), 3.3 (m, 3 H), 3.5 (t, J = 4 Hz, 1 H), 3.9 (m, 2 H), 5.5 (t, J = 4 Hz, 1 H), 6.9 (m, 1 H), 7.1 (m, 1 H), 7.9 (m, 4 H), 8.0 (t, J = 4 Hz, 1), 8.2 (m, 2 H), 8.8 (m, 3 H), 9.2 (s, 1 H), 10.9 (m, 1 H), 13.5 (m, 1 H); mp 87-90°C; MS m/e 490 (MH^+).

EXAMPLES 7-62

Using the procedures described in Examples 1-6 or outlined in Schemes AA-AH and the appropriate reagents and starting materials known to those skilled in the art, other compounds of the present invention may be prepared including, but not limited to:

Cpd	Sch	Salt	MH ⁺
7	AC	TFA	500
8	AC	TFA	522
9	AA	Li	439
10	AH	Li	501
11	AA	TFA	529
12	AA	TFA	489
13	AC	Li	507
14	AA	TFA	527
15	AC	TFA	499
16	AA	TFA	503
17	AA	TFA	527
18	AA	TFA	614
19	AA	TFA	534
20	AA	HCl	436
21	AA	HCl	474
22	AA	HCl	444
23	AA	HCl	472
24	AA	HCl	490
25	AA	HCl	431
26	AA	HCl	499

Cpd	Sch	Salt	MH ⁺
27	AA	HCl	498
28	AH	HCl	505
29	AH	HCl	476
30	AC	HCl	440
31	AH	HCl	433
32	AA	HCl	448
33	AA	HCl	431
34	AA	HCl	490
35	AH	HCl	468
36	AA	HCl	480
37	AA	HCl	480
38	AA	HCl	466
39	AH	HCl	483
40	AH	HCl	433
41	AC	HCl	526
42	AA	HCl	517
43	AA	HCl	466
44	AA	HCl	495
45	AA	---	694
46	AA	HCl	594

Cpd	Sch	Salt	MH ⁺
47	AA	TFA	517
48	AA	TFA	458
49	AA	TFA	529
50	AA	TFA	461
51	AA	HCl	517
52	AA	HCl	431
53	AA	TFA	551
54	AA	TFA	517
55	AA	HCl	501
56	AA	HCl	435
57	AG	HCl	520
58	AE	HCl	479
59	AF	HCl	568
60	AE	HCl	505
61	AE	HCl	476
62	AC	HCl	483

EXAMPLE 63

As a specific embodiment of an oral composition, 100 mg of the Compound 1 of Example 1 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.

EXAMPLE 64*IN VITRO SOLID PHASE PURIFIED $\alpha v \beta 3$ BINDING ASSAY*

The vitronectin/ $\alpha v \beta 3$ binding assay methods were derived from Mehta et al. (10) (*Biochem J.* **1998**, 330, 861). Human $\alpha v \beta 3$ (Chemicon International Inc., Temecula, CA), at a concentration of 1 μ g/ml dissolved in Tris buffer (20 mM Tris, 1 mM CaCl₂, 1 mM MgCl₂, 10 μ M MnCl₂, 150 mM NaCl), was immobilized

on Immulon 96 well plates (Dynex Technologies, Chantilly, VA) overnight at 4 °C. Plates were washed and treated with blocking buffer (3 % BSA in Tris buffer) for 2 h at 37 °C. Plates were then rinsed 2 times with Tris buffer containing 0.3% BSA and 0.2% Tween20 (polyoxyethylenesorbitan monolaurate). Five minutes prior to the addition of 5 nM vitronectin (Sigma, St. Louis, MO), synthesized compounds were added to wells in duplicate. Each plate included c-RGDfV as an internal control. Following a 3 hour incubation at 37 °C, plates were washed 5 times in assay buffer. An anti-human vitronectin IgG rabbit polyclonal antibody (Calbiochem, San Diego, CA) was added (1:2000) and plates were incubated for 1 hour at room temperature. VectaStain ABC peroxidase kit reagents (Vector Laboratories, Burlingame, CA) employing a biotin labeled anti-rabbit IgG, were utilized for detection of bound antibody. Plates were read at 490 nm on a Molecular Devices (Sunnyvale, CA) microplate reader. Table 1 shows the results of the in vitro solid phase purified $\alpha v \beta 3$ binding assay for representative compounds of the present invention.

EXAMPLE 65

IN VITRO SOLID PHASE PURIFIED GP IIB/IIIA BINDING ASSAY

A 96 well Immulon-2 microtiter plate (Dynatech-Immulon) was coated with 50 μ l/well of RGD-affinity purified GPIIb/IIIa (effective range 0.5-10 μ g/mL) in 10 mM HEPES, 150 mM NaCl, 1 mM $MgCl_2$ at pH 7.4. The plate was covered and incubated overnight at 4 °C. The GPIIb/IIa solution was discarded and 150 μ l of 5% BSA was added and incubated at RT for 1-3 h. The plate was washed extensively with modified Tyrodes buffer. Biotinylated fibrinogen (25 μ l/well) at 2 x final concentration was added to the wells that contain the test compounds (25 μ l/well). The plate was covered and incubated at RT for 2-4 h. Twenty minutes prior to incubation completion, one drop of Reagent A (VectaStain ABC Horse Radish Peroxidase kit, Vector Laboratories, Inc.) and one drop Reagent B were added with mixing to 5 mL modified Tyrodes buffer mix and let stand. The ligand solution was discarded and the plate washed (5 x 200 μ l/well) with modified Tyrodes buffer. Vecta Stain HRP-Biotin-Avidin reagent (50 μ l/well, as prepared above) was added and incubated at RT for 15

min. The Vecta Stain solution was discarded and the wells washed (5 x 200 μ l/well) with modified Tyrodes buffer. Developing buffer (10 mL of 50 mM citrate/phosphate buffer @ pH 5.3, 6 mg o-phenylenediamine, 6 μ l 30% H_2O_2 ; 50 μ l/well) was added and incubated at RT for 3-5 min, and then 2 N H_2SO_4 (50 μ l/well) was added. The absorbance was read at 490 nM. Table 1 shows the results of the in vitro solid phase purified GPIIb/IIIa binding assay for representative compounds of the present invention.

EXAMPLE 66

10 *IN VITRO SOLID PHASE PURIFIED $\alpha_v\beta_5$ BINDING ASSAY*

The vitronectin/ $\alpha_v\beta_5$ binding assay method was performed in the same manner as the vitronectin/ $\alpha_v\beta_3$ binding assay (EXAMPLE 64) immobilizing with 1 μ g/ml of human purified $\alpha_v\beta_5$ (Chemicon International, Inc.) on to Immulon 96 well plates (Dynex Technologies) instead of $\alpha_v\beta_3$. All other aspects of the assay including buffers, reagents, and incubation times remain unchanged.

TABLE I

No.	$\alpha_v\beta_3$ IC ₅₀ (uM)	IIb/IIIa IC ₅₀ (uM)	$\alpha_v\beta_5$ IC ₅₀ (uM)
1	0.0037	0.030	0.025
2	0.0058	0.0089	0.021
3	0.028	0.13	NT
4	0.15	1.70	NT
5	0.015	0.023	NT
6	0.0040	0.46	NT
7	0.49	7.9	NT
8	0.55	1.1	NT
9	30	0.30	NT
10	>50	0.95	NT
11	1.3	0.0026	NT
12	0.020	0.014	NT
13	10	29	NT
14	0.050	0.0092	NT
15	>5	17	NT
16	0.019	0.018	0.038
17	0.38	0.0054	NT
18	0.050	0.015	NT
19	0.32	0.071	NT
20	0.53	4.9	NT
21	0.023	0.41	NT
22	>0.5	38	NT
23	>0.5	7.3	NT
24	0.064	2.2	NT
25	0.032	2.9	NT
26	0.12	1.8	NT
27	>0.5	13	NT
28	0.0082	1.5	NT

29	0.034	0.21	NT
30	0.14	56	NT
31	0.029	4.2	NT
32	0.12	3.6	NT
33	0.019	1.8	NT
34	0.029	1.5	>5.0
35	0.14	1.6	NT
36	>0.3	12	NT
37	0.29	1.7	NT
38	>0.3	3.3	NT
39	0.0023	0.036	NT
40	0.012	1.1	NT
41	>0.3	0.11	NT
42	0.17	0.14	NT
43	0.23	1.3	NT
44	0.028	0.36	2.9
45	3.7	14	40%*
46	0.15	1.6	>5
47	0.0040	0.028	NT
48	0.51	1.1	NT
49	0.039	0.012	0.21
50	3.9	0.0074	38%*
51	0.27	0.29	2
52	0.25	2.7	0.76
53	0.57	0.0015	NT
54	0.072	0.013	NT
55	0.012	0.026	0
56	>5	0.049	NT
57	0.35	0.13	NT
58	0.040	0.26	0.071
59	0.16	0.51	NT
60	0.027	0.19	0.086


61	0.18	2.7	NT
62	>0.50	0.38	NT

* Percent inhibition at 5 μ M.

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

WHAT IS CLAIMED IS:

1. A compound of the Formula (I):



wherein

- 5 M is selected from the group consisting of C₁-C₄ alkylene (optionally substituted within the carbon chain with one substituent selected from the group consisting of C₁-C₄ alkyl, C₂-C₄ alkenyl, cycloalkyl (wherein a ring carbon atom forms the point of attachment to the carbon chain) and aryl (optionally substituted with halogen) and substituted on the terminal carbon with one
- 10 substituent selected from A), C₂-C₄ alkenylene (substituted with one substituent selected from A); heterocyclylene (optionally substituted with one substituent selected from A), heterocyclenylene (substituted with one substituent selected from A), arylene (substituted with one substituent selected from A), (C₁-C₄ alkylene)aryl (substituted on C₁-C₄ alkylene with one substituent selected from A) and arylene(C₁-C₄)alkyl (substituted on arylene with one substituent selected from A);
- 15

- A is optionally present and is selected from the group consisting of heteroaryl, heterocyclyl, R₃HN-, (heteroaryl)amino, (heterocyclyl)amino, R₃HNC(=NH)-, R₃HNC(=NH)NH-, R₃HNC(=O)NH-, R₃C(=NH)NH-, (heterocyclyl)aminooxy, (heteroaryl)aminooxy, R₃HNC(=NH)NHO-, R₃C(=NH)NHO-, R₃HNC(=NH)NHC(=O)- and R₃C(=NH)NHC(=O)-; wherein heteroaryl and heterocyclyl are optionally substituted with one to five substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, heteroaryl (optionally substituted with C₁-C₄ alkyl), halogen, hydroxy, nitro, cyano, trihalo(C₁-C₄)alkyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxycarbonyl, aryl(C₁-C₄)alkoxycarbonyl, R₃HN-, amino(C₁-C₄)alkyl, C₁-C₄ alkylamino(C₁-C₄)alkyl and di(C₁-C₄ alkyl)amino(C₁-C₄)alkyl;
- 20
- 25

with the proviso that if A is $\text{H}_2\text{NC(=NH)NH-}$, then, dependently, W is not hydrogen when Q is $-\text{CH}_2-$;

- 5 L is selected from the group consisting of $-\text{C(=O)-}$, $-\text{SO}_2-$, $-\text{OC(=O)-}$ and $-\text{HNC(=O)-}$;

R_1 is selected from the group consisting of hydrogen, C_1 - C_8 alkyl and cycloalkyl;

10

R_2 is selected from the group consisting of hydrogen and C_1 - C_8 alkyl;

R_3 is selected from the group consisting of hydrogen, C_1 - C_8 alkyl, aryl, aryl(C_1 - C_8)alkyl, cycloalkyl, hydroxy, cyano and nitro;

15

Q is selected from the group consisting of $-\text{CH}_2-$, $-\text{CH}(\text{C}_1\text{-C}_8\text{alkyl})-$, $-\text{CH}(\text{C}_2\text{-C}_8\text{alkenyl})-$, $-\text{CH}(\text{C}_2\text{-C}_8\text{alkynyl})-$, $-\text{CH}(\text{aryl})-$ (wherein aryl is optionally substituted with one to five substituents independently selected from the group consisting of C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-\text{O}(\text{C}_1\text{-C}_3\text{ alkyl})-\text{O}-$, halogen, hydroxy, trihalo($\text{C}_1\text{-C}_3$)alkyl and trihalo($\text{C}_1\text{-C}_3$)alkoxy), $-\text{CH}(\text{heteroaryl})-$ (wherein heteroaryl is optionally substituted with a substituent selected from the group consisting of halogen, hydroxy, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-\text{O}(\text{C}_1\text{-C}_3\text{ alkyl})-\text{O}-$, amino, C_1 - C_4 alkylamino and di($\text{C}_1\text{-C}_4$)alkylamino) and $-\text{CH}(\text{aryl}(\text{C}_1\text{-C}_8)\text{alkyl})-$;

25

W is selected from the group consisting of hydrogen and $\text{N}(\text{R}_4)\text{T}$;

r is an integer selected from 0 or 1;

- 30 R_4 is selected from the group consisting of hydrogen, C_1 - C_8 alkyl and C_2 - C_6 acyl;

T is selected from the group consisting of $\text{R}_5\text{C(=O)-}$, $\text{R}_5\text{OC(=O)-}$ and $\text{R}_5\text{C(=N-}$

CN)-;

R₅ is selected from the group consisting of C₁-C₈ alkyl, aryl, aryl(C₁-C₈)alkyl and amino (wherein amino is optionally substituted with one to two substituents independently selected from C₁-C₈ alkyl);

R₆ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, aryl(C₁-C₈)alkyl, (R₇)N(C₁-C₈)alkyl, (R₈)(R₇)N(C₁-C₈)alkyl and (R₈)(R₇)NC(=O)(C₁-C₈)alkyl; and,

R₇ and R₈ are independently selected from the group consisting of hydrogen, C₁-C₈ alkyl and cycloalkyl;

and pharmaceutically acceptable salts thereof.

15

2. The compound of Claim 1, wherein

M is selected from the group consisting of ethylene (optionally substituted within the carbon chain with methyl and substituted on the terminal carbon with one substituent selected from A), propylene (optionally substituted within the carbon chain with a substituent selected from the group consisting of methyl, ethenyl, cyclohexylidene (wherein a ring carbon atom forms the point of attachment to the carbon chain) and 4-Cl-phenyl and substituted on the terminal carbon with one substituent selected from A), allylene (substituted with one substituent selected from A); piperidin-4-ylene (optionally substituted with one substituent selected from A), 1,4,5-dihydro-2-cyclopenten-1-yl (substituted with one substituent selected from A) and 4-methylphenylene (substituted on methylene with one substituent selected from A);

A is optionally present and is selected from the group consisting of 1*H*-imidazol-1-yl, 1*H*-imidazol-2-yl, 4,5-dihydro-1*H*-imidazol-2-yl (optionally substituted with a substituent selected from the group consisting of C₁-C₄ alkoxycarbonyl and aryl(C₁-C₄)alkoxycarbonyl), pyridin-2-yl (optionally

- substituted with a substituent selected from the group consisting of C₁-C₄ alkyl, heteroaryl [optionally substituted with C₁-C₄ alkyl], halogen, hydroxy, nitro, cyano, amino, amino(C₁-C₄)alkyl, C₁-C₄ alkylamino(C₁-C₄)alkyl and di(C₁-C₄ alkyl)amino(C₁-C₄)alkyl), pyrimidin-2-yl, 1,4,5,6-tetrahydro-
 5 pyrimidin-2-yl (optionally substituted with one to two substituents independently selected from the group consisting of C₁-C₄ alkyl, hydroxy and amino), piperidin-4-yl, benzimidazol-2-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-7-yl, 3*H*-imidazo[4,5-*b*]pyridin-2-yl, amino, (C₁-C₆ alkyl)amino, (1*H*-imidazol-1-yl)amino, (1*H*-imidazol-2-yl)amino, (4,5-dihydro-1*H*-imidazol-
 10 2-yl)amino (optionally substituted on 4,5-dihydro-1*H*-imidazol-2-yl with a substituent selected from the group consisting of (C₁-C₆)alkoxycarbonyl and aryl(C₁-C₆)alkoxycarbonyl), (pyridin-2-yl)amino (optionally substituted on pyridin-2-yl with a substituent selected from the group consisting of C₁-C₄ alkyl, heteroaryl [optionally substituted with C₁-C₄ alkyl], halogen, hydroxy,
 15 nitro, cyano, amino, amino(C₁-C₄)alkyl, C₁-C₄ alkylamino(C₁-C₄)alkyl and di(C₁-C₄ alkyl)amino(C₁-C₄)alkyl), (pyrimidin-2-yl)amino, (1,4,5,6-tetrahydropyrimidin-2-yl)amino (optionally substituted on 1,4,5,6-tetrahydropyrimidin-2-yl with one to two substituents independently selected from the group consisting of C₁-C₄ alkyl, hydroxy and amino), (4,5,6,7-
 20 tetrahydro-1*H*-1,3-diazepin-2-yl)amino, (thiazol-2-yl)amino, (benzimidazol-2-yl)amino, (3*H*-imidazo[4,5-*b*]pyridin-2-yl)amino, R₃HNC(=NH)NH-, R₃HNC(=O)NH-, (4,5,6,7-tetrahydro-1*H*-1,3-diazepin-2-yl)aminooxy, (4,5-dihydro-1*H*-imidazol-2-yl)aminooxy and R₃HNC(=NH)NHO-;
- 25 with the proviso that if A is H₂NC(=NH)NH-, then, dependently, W is not hydrogen when Q is -CH₂-;

L is selected from the group consisting of -C(=O)-, -OC(=O)- and -HNC(=O)-;

- 30 R₁ is selected from the group consisting of hydrogen and C₁-C₄ alkyl;

R₂ is hydrogen;

R₃ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, aryl(C₁-C₈)alkyl and hydroxy;

Q is selected from the group consisting of -CH₂-, -CH(C₁-C₈alkyl)-, -CH(aryl)-

5 (wherein aryl is optionally substituted with one to five substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, -O-(C₁-C₃ alkyl)-O-, halogen, hydroxy and trihalo(C₁-C₃)alkyl), -CH(heteroaryl)- (wherein heteroaryl is optionally substituted with a substituent selected from halogen) and -CH(aryl(C₁-C₈)alkyl)-;

10

r is 1;

R₄ is selected from the group consisting of hydrogen and C₁-C₄ alkyl;

15 T is selected from the group consisting of R₅C(=O)- and R₅OC(=O)-;

R₅ is selected from the group consisting of aryl and aryl(C₁-C₄)alkyl;

R₆ is selected from the group consisting of hydrogen, methyl and

20 (R₈)(R₇)NC(=O)CH₂; and,

R₇ and R₈ are independently selected from the group consisting of hydrogen, methyl and ethyl;

25 and pharmaceutically acceptable salts thereof.

3. The compound of Claim 2, wherein

A is optionally present and is selected from the group consisting of

30 1*H*-imidazol-1-yl, 4,5-dihydro-1*H*-imidazol-2-yl, pyridin-2-yl (optionally substituted with a substituent selected from the group consisting of C₁-C₄ alkyl and heteroaryl [optionally substituted with C₁-C₄ alkyl]), piperidin-4-yl, benzimidazol-2-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-7-yl, 3*H*-imidazo[4,5-*b*]pyridin-2-yl, amino, (4,5-dihydro-1*H*-imidazol-2-yl)amino (optionally

substituted on 4,5-dihydro-1*H*-imidazol-2-yl with C₁-C₆ alkoxy carbonyl),
 (pyridin-2-yl)amino (optionally substituted on pyridinyl with a substituent
 selected from the group consisting of C₁-C₄ alkyl and heteroaryl (optionally
 substituted with C₁-C₄ alkyl)), (1,4,5,6-tetrahydro-5-hydroxypyrimidin-2-
 5 yl)amino, (1,4,5,6-tetrahydro-5-methylpyrimidin-2-yl)amino, (1,4,5,6-
 tetrahydro-5,5-dimethylpyrimidin-2-yl)amino, (thiazol-2-yl)amino,
 (3*H*-imidazo[4,5-*b*]pyridin-2-yl)amino, R₃HNC(=NH)NH-, R₃HNC(=O)NH-,
 (4,5-dihydro-1*H*-imidazol-2-yl)aminooxy and R₃HNC(=NH)NHO-;

10 with the proviso that if A is H₂NC(=NH)NH-, then, dependently, W is not
 hydrogen when Q is -CH₂-;

R₁ is hydrogen;

15 R₃ is selected from the group consisting of hydrogen, butyl, benzyl and
 hydroxy;

Q is selected from the group consisting of -CH₂-, -CH(methyl)-, -CH(ethyl)-,
 -CH(phenyl)- (wherein phenyl is optionally substituted with one to five
 20 substituents independently selected from the group consisting of methyl,
 ethyl, propyl, methoxy, ethoxy, propoxy, bromine, chlorine, fluorine, iodine,
 hydroxy and trifluoromethyl), -CH(naphthalen-1-yl)-, -CH(naphthalen-2-yl)-,
 -CH((3,4-dioxymethylene)phenyl)-, -CH((3,4-dioxyethylene)phenyl)-,
 -CH((3-bromo-5-chloro-2-hydroxy)phenyl)-, -CH(thien-3-yl)-,
 25 -CH(quinolin-3-yl)-, -CH(pyridin-3-yl)- (wherein pyridinyl is optionally
 substituted with chlorine) and -CH(benzyl)-;

R₄ is hydrogen;

30 T is selected from R₅OC(=O)-;

R₅ is selected from aryl(C₁-C₄)alkyl;

R₆ is hydrogen; and,

R₇ and R₈ are independently ethyl;

5 and pharmaceutically acceptable salts thereof.

4. The compound of Claim 3, wherein

A is optionally present and is selected from the group consisting of 4,5-dihydro-
1*H*-imidazol-2-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-7-yl, 3*H*-imidazo[4,5-
10 *b*]pyridin-2-yl, amino, (4,5-dihydro-1*H*-imidazol-2-yl)amino, (pyridin-2-
yl)amino, (3-methylpyridin-2-yl)amino, (thiazol-2-yl)amino, (3*H*-imidazo[4,5-
b]pyridin-2-yl)amino, NH₂C(=NH)NH-, R₃HNC(=O)NH-, (4,5-dihydro-1*H*-
imidazol-2-yl)aminoxy and NH₂C(=NH)NHO-,

15 with the proviso that if A is H₂NC(=NH)NH-, then, dependently, W is not
hydrogen when Q is -CH₂-;

Q is selected from the group consisting of -CH₂-, -CH(methyl)-, -CH(phenyl)-
(wherein phenyl is optionally substituted with one to five substituents
20 independently selected from the group consisting of methyl, methoxy,
bromine, chlorine, fluorine, hydroxy and trifluoromethyl),
-CH(naphthalen-1-yl)-, -CH(naphthalen-2-yl)-,
-CH((3,4-dioxymethylene)phenyl)-, -CH((3,4-dioxyethylene)phenyl)-,
-CH((3-bromo-5-chloro-2-hydroxy)phenyl)-, -CH(thien-3-yl)-,
25 -CH(quinolin-3-yl)-, -CH(pyridin-3-yl)- (wherein pyridinyl is optionally
substituted with chlorine) and -CH(benzyl)-; and,

R₅ is benzyl;

30 and pharmaceutically acceptable salts thereof.

5. The compound of Claim 1 selected from the group consisting of:

β-[[[1-[4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-1-oxobutyl]-4-

piperidinyl]carbonyl]amino]-, (β^3S)- 3-quinolinepropanoic acid;
 3-[[[1-[4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-1-oxobutyl]-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
 β -[[[1-[1-oxo-4-(2-pyridinylamino)butyl]-4-piperidinyl]carbonyl]amino]-, (β^3S)- 3-quinolinepropanoic acid;
 3-[[[1-[1-(4,5-dihydro-1*H*-imidazol-2-yl)-4-piperidinyl]carbonyl]-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
 3-[[[1-[(1*S*,4*R*)-4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-2-cyclopenten-1-yl]carbonyl]-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
 3-[[[1-[3-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-2-methyl-1-oxopropyl]-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
 3-[[[1-[(1*R*,4*S*)-4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-2-cyclopenten-1-yl]carbonyl]-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
 4-[[[(2*S*)-2-carboxy-2-[(phenylmethoxy)carbonyl]amino]ethyl]amino]carbonyl]-, 2-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]ethyl ester 1-piperidinecarboxylic acid;
 β -[[[1-[2-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]ethoxy]carbonyl]-4-piperidinyl]carbonyl]amino]-, (β^3S)- 3-quinolinepropanoic acid;
 3-[[[1-[4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]-2-methyl-1-oxobutyl]-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
 3-[[[1-(4-amino-1-oxo-5-hexenyl)-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
 3-[[[1-[4-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]methyl]benzoyl]-4-piperidinyl]carbonyl]amino]-*N*-[(phenylmethoxy)carbonyl]- L-alanine;
 β -[[[1-[3-[(4,5-dihydro-1*H*-imidazol-2-yl)amino]oxy]-1-oxopropyl]-4-piperidinyl]carbonyl]amino]- 1,3-benzodioxole-5-propanoic acid;
 and,
 β -[[[1-[1-oxo-4-(2-pyridinylamino)butyl]-4-piperidinyl]carbonyl]amino]- 1,3-benzodioxole-5-propanoic acid;

and pharmaceutically acceptable salts thereof.

6. The compound of Claim 1 which are effective integrin antagonists.

5

7. The compound of Claim 6 which are effective $\alpha v\beta 3$, $\alpha v\beta 5$, GPIIb/IIIa, dual $\alpha v\beta 3$ /GPIIb/IIIa or dual $\alpha v\beta 3/\alpha v\beta 5$ integrin antagonists.

8. The compound of Claim 7 which are effective $\alpha v\beta 3$ integrin antagonists

10

selected from the group consisting of Compound 1, 2, 3, 5, 6, 12, 14,

16, 18, 21, 24, 25, 28, 29, 31, 33, 34, 39, 40, 44, 47, 49, 54, 55, 58 and 60.

5 9. The compound of claim 8 wherein the compound is selected from the group consisting of Compound **1, 2, 6, 28, 39 and 47.**

10. The compound of Claim 7 which are effective GPIIb/IIIa integrin antagonists selected from the group consisting of Compound **1, 2, 5, 11, 12, 14, 16, 17, 18, 19, 39, 47, 49, 50, 53, 54, 55 and 56.**

10

11. The compound of claim 10 wherein the compound is selected from the group consisting of Compound **2, 11, 14, 17, 50 and 53.**

15 12. The compound of Claim 7 which are effective $\alpha v\beta 5$ integrin antagonists selected from the group consisting of Compound **1, 2, 16, 45, 58 and 60.**

13. The compound of claim 12 wherein the compound is selected from the group consisting of Compound **1, 2 and 16.**

20

14. The compound of Claim 7 which are effective dual $\alpha v\beta 3$ /GPIIb/IIIa integrin antagonists selected from the group consisting of Compound **2, 5, 12, 14, 16, 18, 39, 47, 49, 54 and 55.**

25 15. The compound of claim 14 wherein the compound is Compound **2.**

16. The compound of Claim 7 which are effective dual $\alpha v\beta 3/\alpha v\beta 5$ integrin antagonists selected from the group consisting of Compound **1, 2, 16, 58 and 60.**

30

17. The compound of claim 16 wherein the compound is selected from the group consisting of Compound **1 and 2.**

18. The compound of Claim 1 which are effective agents for the treatment of an integrin-mediated disorder ameliorated by administration of an integrin antagonist.
- 5 19. The compound of Claim 18 wherein the integrin-mediated disorder is selected from the group consisting of restenosis, unstable angina, thromboembolic disorders, vascular injury, atherosclerosis, arterial thrombosis, venous thrombosis, vaso-occlusive disorders, acute myocardial infarction, re-occlusion following thrombolytic therapy, re-
10 occlusion following angioplasty, inflammation, rheumatoid arthritis, osteoporosis, bone resorption disorders, cancer, tumor growth, angiogenesis, multiple sclerosis, neurological disorders, asthma, macular degeneration, diabetic complications and diabetic retinopathy.
- 15 20. The compound of Claim 1 which are effective prodrugs selected from the group consisting of esters, hydroxyamidines and hydroxyguanidines of compounds of Claim 1.
- 20 21. The compound of Claim 20 which are effective agents for the treatment of an integrin-mediated disorder ameliorated by administration of an integrin antagonist.
- 25 22. The compound of Claim 21 wherein the integrin-mediated disorder is selected from the group consisting of restenosis, unstable angina, thromboembolic disorders, vascular injury, atherosclerosis, arterial thrombosis, venous thrombosis, vaso-occlusive disorders, acute myocardial infarction, re-occlusion following thrombolytic therapy, re-
occlusion following angioplasty, inflammation, rheumatoid arthritis, osteoporosis, bone resorption disorders, cancer, tumor growth,
30 angiogenesis, multiple sclerosis, neurological disorders, asthma, macular degeneration, diabetic complications and diabetic retinopathy.
23. A pharmaceutical composition comprising a compound of Claim 1 and a

pharmaceutically acceptable carrier.

24. A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 5
25. A process for making a pharmaceutical composition comprising mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 10
26. A method of treating an integrin-mediated disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Claim 1.
- 15
27. The method of Claim 26 wherein the integrin-mediated disorder is selected from the group consisting of restenosis, unstable angina, thromboembolic disorders, vascular injury, atherosclerosis, arterial thrombosis, venous thrombosis, vaso-occlusive disorders, acute myocardial infarction, re-occlusion following thrombolytic therapy, re-occlusion following angioplasty, inflammation, rheumatoid arthritis, osteoporosis, bone resorption disorders, cancer, tumor growth,
- 20
- angiogenesis, multiple sclerosis, neurological disorders, asthma, macular degeneration, diabetic complications and diabetic retinopathy.
28. The method of Claim 26 wherein the therapeutically effective amount of the compound of Claim 1 is between about 0.01 mg/kg/day and about
- 25
- 300 mg/kg/day.
29. A method of treating an integrin-mediated disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a prodrug of Claim 20.
- 30
30. The method of Claim 29 wherein the integrin-mediated disorder is selected from the group consisting of restenosis, unstable angina, thromboembolic disorders, vascular injury, atherosclerosis, arterial

thrombosis, venous thrombosis, vaso-occlusive disorders, acute myocardial infarction, re-occlusion following thrombolytic therapy, re-occlusion following angioplasty, inflammation, rheumatoid arthritis, osteoporosis, bone resorption disorders, cancer, tumor growth,
5 angiogenesis, multiple sclerosis, neurological disorders, asthma, macular degeneration, diabetic complications and diabetic retinopathy.

31. The method of Claim 29, wherein the therapeutically effective amount of the prodrug of Claim 20 is between about 0.01 mg/kg/day and about
10 300 mg/kg/day.

32. A method of treating an integrin-mediated disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of Claim 23.
15

33. The method of Claim 32 wherein the integrin-mediated disorder is selected from the group consisting of restenosis, unstable angina, thromboembolic disorders, vascular injury, atherosclerosis, arterial thrombosis, venous thrombosis, vaso-occlusive disorders, acute
20 myocardial infarction, re-occlusion following thrombolytic therapy, re-occlusion following angioplasty, inflammation, rheumatoid arthritis, osteoporosis, bone resorption disorders, cancer, tumor growth, angiogenesis, multiple sclerosis, neurological disorders, asthma, macular degeneration, diabetic complications and diabetic retinopathy.
25

34. The method of Claim 32, wherein the therapeutically effective amount of the pharmaceutical composition of Claim 23 is between about 0.01 mg/kg/day and about 300 mg/kg/day.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/26163

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/14 C07D401/12 C07D401/06 C07D211/62 C07D405/14
C07D409/14 C07D417/12 A61K31/454 A61P7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VARON, DAVID ET AL: "Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp" THROMB. HAEMOSTASIS (1993), 70(6), 1030-6 ' XP000979521 summary Fig 1, NS-8, NS-11, NS-12, NS-14 ---	1-7, 18-34
X	US 5 700 801 A (PIEPER HELMUT ET AL) 23 December 1997 (1997-12-23) column 33, line 1 - line 2 --- -/--	1,6,7, 18-34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

5 February 2001

Date of mailing of the international search report

22/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Diederer, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/26163

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SU, TING ET AL: "Fibrinogen Receptor (GPIIb-IIIa) Antagonists Derived from 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the N-.alpha.-Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors" J. MED. CHEM. (1997), 40(26), 4308-4318 , XP000915289 Table 2, compound 25 page 4308, left-hand column, line 1 - line 21 ---	1,6,7, 18-34
X	US 5 922 717 A (HIMMELSBACH FRANK ET AL) 13 July 1999 (1999-07-13) Example 1, (7) ---	1,6,7, 18-34
X	CHEMICAL ABSTRACTS, vol. 118, no. 25, 21 June 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342, HOSODA, AKIHIKO ET AL: "Preparation of N-(heterocyclylcarbonyl)amino acids and analogs as prolyl endopeptidase inhibitors" XP002159418 Compound with RN 129776-63-2 & JP 04 334357 A (FUJIREBIO, INC., JAPAN) 20 November 1992 (1992-11-20) ---	1
P,X	WO 99 67230 A (TANABE SEIYAKU CO ;TEEGARDEN BRADLEY R (US); THOMAS EDWARD WILLIAM) 29 December 1999 (1999-12-29) page 2, line 4 - line 6 examples 173-175 -----	1,6,7, 18-34

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 00 26163

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1 (partially)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty for claim 1. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT).

For these reasons it appears impossible to execute a meaningful search and/or to issue a complete search report over the whole breadth of claim 1. The search and the search report can only be considered complete for claims 2-34, which includes the use in integrin-related diseases of all compounds of claim 1 and compounds of claim 2. All compounds of the examples fall under the latter claim and therefore all examples have been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/26163

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5700801	A	23-12-1997	DE 4446300 A	27-06-1996
			AU 4055895 A	04-07-1996
			BR 9505981 A	23-12-1997
			CA 2165922 A	24-06-1996
			CN 1131665 A	25-09-1996
			DE 19533224 A	13-03-1997
			EP 0718287 A	26-06-1996
			JP 8231509 A	10-09-1996
			PL 311999 A	24-06-1996
			TR 960599 A	21-07-1996
US 5922717	A	13-07-1999	DE 4446301 A	27-06-1996
			DE 19526678 A	23-01-1997
			AU 4432496 A	19-07-1996
			BG 101582 A	30-01-1998
			BR 9510360 A	23-12-1997
			CA 2207618 A	04-07-1996
			CN 1183770 A	03-06-1998
			CZ 9701891 A	14-01-1998
			DE 19533639 A	13-03-1997
			WO 9620173 A	04-07-1996
			EP 0799202 A	08-10-1997
			FI 972646 A	19-08-1997
			HR 950609 A	31-10-1997
			JP 10511374 T	04-11-1998
			NO 972881 A	20-06-1997
			PL 321003 A	24-11-1997
			SK 79797 A	05-11-1997
			TR 960600 A	21-07-1996
JP 4334357	A	20-11-1992	NONE	
WO 9967230	A	29-12-1999	AU 4711699 A	10-01-2000